{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:59:25Z","timestamp":1778774365370,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsche Diabetes Gesellschaft (DDG)"},{"DOI":"10.13039\/501100013294","name":"Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt, Helmholtz Zentrum M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013294","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Research Foundation (DFG)"},{"name":"German Center for Diabetes Research e.V. (DZD e.V.)"},{"name":"Clinical Cooperation Group Diabetes, Ludwig-Maximilians-University Munich and Helmholtz Zentrum M\u00fcnchen"},{"name":"German Diabetes Center (DDZ)"},{"name":"Virtual Institute of Diabetes Research (Helmholtz Zentrum M\u00fcnchen)"},{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>High N-terminal pro-brain-type natriuretic peptide levels have been associated with a lower risk of type 2 diabetes mellitus (T2D). However, less is known about other cardiac stress biomarkers in this context. Here we evaluated the association of mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) with incident T2D and changes in glucose metabolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a prospective cohort study using data from the population-based KORA F4\/FF4 study. 1773 participants (52.3% women) with MR-proANP measurements and 960 (52.7% women) with copeptin, CT-proET-1 and MR-proADM measurements were included. We examined associations of circulating plasma levels of MR-proANP, copeptin, CT-proET-1 and MR-proADM with incident T2D, the\u00a0combined endpoint of\u00a0incident prediabetes\/T2D and with fasting and 2\u00a0h-glucose, fasting insulin, HOMA-IR, HOMA-B and HbA1c at follow-up. Logistic and linear regression models adjusted for age, sex, waist circumference, height, hypertension, total\/HDL cholesterol ratio, triglycerides, smoking, physical activity and parental history of diabetes were used to compute effect estimates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During a median follow-up time of 6.4\u00a0years (25th and 75th percentiles: 6.0 and 6.6, respectively), 119 out of the 1773 participants and 72 out of the 960 participants developed T2D. MR-proANP was inversely associated with incident T2D (odds ratio [95% confidence interval]: 0.75 [0.58; 0.96] per 1-SD increase of log MR-proANP). Copeptin was positively associated with incident prediabetes\/T2D (1.29 [1.02; 1.63] per 1-SD increase of log copeptin). Elevated levels of CT-proET-1 were associated with increased HOMA-B at follow-up, while elevated MR-proADM levels were associated with increased fasting insulin, HOMA-IR and HOMA-B at follow-up. These associations were independent of previously described diabetes risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>High plasma concentrations of MR-proANP contributed to a lower risk of incident T2D, whereas high plasma concentrations of copeptin were associated with an increased risk of incident prediabetes\/T2D. Furthermore, high plasma concentrations of CT-proET-1 and MR-proADM were associated with increased insulin resistance. Our study provides evidence that biomarkers implicated in cardiac stress are associated with incident T2D and changes in glucose metabolism.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-01117-1","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T11:03:09Z","timestamp":1602846189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4\/FF4 study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0663-2557","authenticated-orcid":false,"given":"Chaterina","family":"Sujana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Seissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Rathmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9603","authenticated-orcid":false,"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-093X","authenticated-orcid":false,"given":"Christian","family":"Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-0985","authenticated-orcid":false,"given":"Annette","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-6440","authenticated-orcid":false,"given":"Barbara","family":"Thorand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Then","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"8","key":"1117_CR1","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2337\/diacare.26.8.2433","volume":"26","author":"DS Bell","year":"2003","unstructured":"Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26(8):2433\u201341.","journal-title":"Diabetes Care"},{"issue":"11","key":"1117_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.106.655142","volume":"115","author":"TJ Wang","year":"2007","unstructured":"Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115(11):1345\u201353.","journal-title":"Circulation"},{"issue":"5","key":"1117_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","volume":"109","author":"TJ Wang","year":"2004","unstructured":"Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594\u2013600.","journal-title":"Circulation"},{"issue":"2","key":"1117_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2013.07.047","volume":"230","author":"C Then","year":"2013","unstructured":"Then C, Kowall B, Lechner A, Meisinger C, Heier M, Koenig W, et al. Plasma MR-proANP levels are associated with carotid intima-media thickness in the general community: the KORA F4 study. Atherosclerosis. 2013;230(2):235\u201341.","journal-title":"Atherosclerosis."},{"issue":"6","key":"1117_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1530\/EJE-12-0472","volume":"167","author":"J Seissler","year":"2012","unstructured":"Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W, et al. Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur J Endocrinol. 2012;167(6):847\u201353.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1117_CR6","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1210\/jc.2008-2278","volume":"94","author":"U Saleem","year":"2009","unstructured":"Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94(7):2558\u201364.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"1117_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.arcmed.2020.05.018","volume":"51","author":"T Noor","year":"2020","unstructured":"Noor T, Hanif F, Kiran Z, Rehman R, Khan MT, Haque Z, et al. Relation of copeptin with diabetic and renal function markers among patients with diabetes mellitus progressing towards diabetic nephropathy. Arch Med Res. 2020;51(6):548-55. https:\/\/doi.org\/10.1016\/j.arcmed.2020.05.018.","journal-title":"Arch Med Res."},{"issue":"4","key":"1117_CR8","doi-asserted-by":"publisher","first-page":"e10100","DOI":"10.1371\/journal.pone.0010100","volume":"5","author":"V Salomaa","year":"2010","unstructured":"Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE. 2010;5(4):e10100.","journal-title":"PLoS ONE"},{"issue":"10","key":"1117_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.metabol.2016.06.002","volume":"65","author":"EF Brutsaert","year":"2016","unstructured":"Brutsaert EF, Biggs ML, Delaney JA, Djouss\u00e9 L, Gottdiener JS, Ix JH, et al. Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: the cardiovascular health study. Metab Clin Exp. 2016;65(10):1489\u201397.","journal-title":"Metab Clin Exp"},{"issue":"10","key":"1117_CR10","doi-asserted-by":"publisher","first-page":"e1001112","DOI":"10.1371\/journal.pmed.1001112","volume":"8","author":"R Pfister","year":"2011","unstructured":"Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8(10):e1001112.","journal-title":"PLoS Med."},{"issue":"2","key":"1117_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jc.2011-2425","volume":"97","author":"M Magnusson","year":"2012","unstructured":"Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2012;97(2):638\u201345.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"1117_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13054-018-1955-7","volume":"22","author":"N Nigro","year":"2018","unstructured":"Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Arici B, Bally M, et al. Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hypernatraemia\u2014the \u201cCo-MED study\u201d. Crit Care (London, England). 2018;22(1):33.","journal-title":"Crit Care (London, England)."},{"issue":"1","key":"1117_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cen.13991","volume":"91","author":"J Refardt","year":"2019","unstructured":"Refardt J, Winzeler B, Christ-Crain M. Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis. Clin Endocrinol. 2019;91(1):22\u201332.","journal-title":"Clin Endocrinol"},{"issue":"19","key":"1117_CR14","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1161\/CIRCULATIONAHA.109.909663","volume":"121","author":"S Enhorning","year":"2010","unstructured":"Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121(19):2102\u20138.","journal-title":"Circulation"},{"issue":"6","key":"1117_CR15","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1210\/jc.2016-1113","volume":"101","author":"R Roussel","year":"2016","unstructured":"Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, et al. Plasma Copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab. 2016;101(6):2432\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"1117_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijcard.2017.10.035","volume":"250","author":"N Suthahar","year":"2018","unstructured":"Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, et al. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol. 2018;250:188\u201394.","journal-title":"Int J Cardiol"},{"issue":"7","key":"1117_CR17","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00125-012-2545-x","volume":"55","author":"A Abbasi","year":"2012","unstructured":"Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012;55(7):1963\u201370.","journal-title":"Diabetologia"},{"issue":"11","key":"1117_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0895-7061(02)03060-1","volume":"15","author":"JG Schneider","year":"2002","unstructured":"Schneider JG, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967\u201372.","journal-title":"Am J Hypertens"},{"issue":"9","key":"1117_CR19","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/BF00400650","volume":"39","author":"S Gregersen","year":"1996","unstructured":"Gregersen S, Thomsen JL, Brock B, Hermansen K. Endothelin-1 stimulates insulin secretion by direct action on the islets of Langerhans in mice. Diabetologia. 1996;39(9):1030\u20135.","journal-title":"Diabetologia"},{"issue":"5","key":"1117_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/01.HYP.0000066846.46422.2C","volume":"41","author":"T Shimosawa","year":"2003","unstructured":"Shimosawa T, Ogihara T, Matsui H, Asano T, Ando K, Fujita T. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension (Dallas, Tex: 1979). 2003;41(5):1080\u20135.","journal-title":"Hypertension (Dallas, Tex: 1979)."},{"issue":"2","key":"1117_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00125-002-1025-0","volume":"46","author":"W Rathmann","year":"2003","unstructured":"Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46(2):182\u20139.","journal-title":"Diabetologia."},{"key":"1117_CR22","unstructured":"World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health Organization; 1999."},{"issue":"4","key":"1117_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10654-018-0475-8","volume":"34","author":"C Huth","year":"2019","unstructured":"Huth C, von Toerne C, Schederecker F, de Gala LHT, Herder C, Kronenberg F, et al. Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4\/FF4 study. Eur J Epidemiol. 2019;34(4):409\u201322.","journal-title":"Eur J Epidemiol."},{"issue":"8","key":"1117_CR24","doi-asserted-by":"publisher","first-page":"e22932","DOI":"10.1371\/journal.pone.0022932","volume":"6","author":"IM R\u00fcckert","year":"2011","unstructured":"R\u00fcckert IM, Heier M, Rathmann W, Baumeister SE, D\u00f6ring A, Meisinger C. Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. PLoS ONE. 2011;6(8):e22932.","journal-title":"PLoS ONE"},{"issue":"3","key":"1117_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"2","key":"1117_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.7326\/M13-1522","volume":"160","author":"MJ Leening","year":"2014","unstructured":"Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician\u2019s guide. Ann Intern Med. 2014;160(2):122\u201331.","journal-title":"Ann Intern Med"},{"key":"1117_CR27","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020."},{"issue":"1","key":"1117_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00125-013-3061-3","volume":"57","author":"C Herder","year":"2014","unstructured":"Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia. 2014;57(1):16\u201329.","journal-title":"Diabetologia"},{"issue":"1","key":"1117_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/sim.4085","volume":"30","author":"MJ Pencina","year":"2011","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11\u201321.","journal-title":"Stat Med"},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2016.07.905","volume":"252","author":"C Then","year":"2016","unstructured":"Then C, Rottenkolber M, Lechner A, Meisinger C, Heier M, Koenig W, et al. Altered relation of the renin-aldosterone system and vasoactive peptides in type 2 diabetes: the KORA F4 study. Atherosclerosis. 2016;252:88\u201396.","journal-title":"Atherosclerosis."},{"issue":"11","key":"1117_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1161\/01.CIR.0000141736.76561.78","volume":"110","author":"A Prasad","year":"2004","unstructured":"Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004;110(11):1507\u201312.","journal-title":"Circulation"},{"issue":"4","key":"1117_CR32","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1210\/jc.2015-3518","volume":"101","author":"A Jujic","year":"2016","unstructured":"Jujic A, Nilsson PM, Persson M, Holst JJ, Torekov SS, Lyssenko V, et al. Atrial natriuretic peptide in the high normal range is associated with lower prevalence of insulin resistance. J Clin Endocrinol Metab. 2016;101(4):1372\u201380.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"1117_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.118.11081","volume":"72","author":"J Jordan","year":"2018","unstructured":"Jordan J, Birkenfeld AL, Melander O, Moro C. Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management. Hypertension (Dallas, Tex: 1979). 2018;72(2):270\u20136.","journal-title":"Hypertension (Dallas, Tex: 1979)."},{"issue":"5","key":"1117_CR34","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00125-007-0614-3","volume":"50","author":"C Moro","year":"2007","unstructured":"Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia. 2007;50(5):1038\u201347.","journal-title":"Diabetologia"},{"issue":"9","key":"1117_CR35","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1210\/JC.2015-2362","volume":"100","author":"SG Wannamethee","year":"2015","unstructured":"Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab. 2015;100(9):3332\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1117_CR36","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","volume":"92","author":"TA Koshimizu","year":"2012","unstructured":"Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813\u201364.","journal-title":"Physiol Rev"},{"issue":"1","key":"1117_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","volume":"18","author":"A Bosch","year":"2019","unstructured":"Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, et al. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44.","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"1117_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jjcc.2018.11.008","volume":"73","author":"Y Yoshikawa","year":"2019","unstructured":"Yoshikawa Y, Shiomi H, Kuwahara K, Sowa N, Yaku H, Yamashita Y, et al. Utility of copeptin for predicting long-term clinical outcomes in patients with heart failure. J Cardiol. 2019;73(5):379\u201385.","journal-title":"J Cardiol"},{"issue":"1","key":"1117_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-018-0753-5","volume":"17","author":"G Velho","year":"2018","unstructured":"Velho G, Ragot S, El Boustany R, Saulnier PJ, Fraty M, Mohammedi K, et al. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):110.","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"1117_CR40","first-page":"553","volume":"35","author":"I Sahin","year":"2012","unstructured":"Sahin I, Celik O, Celik N, Keskin L, Dogru A, Dogru I, et al. Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome. J Endocrinol Invest. 2012;35(6):553\u20136.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1117_CR41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2337\/dc06-1899","volume":"30","author":"SC Lim","year":"2007","unstructured":"Lim SC, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK, Sum CF. The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes Care. 2007;30(6):1513\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"1117_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0026-0495(00)91585-3","volume":"49","author":"S Gregersen","year":"2000","unstructured":"Gregersen S, Thomsen JL, Hermansen K. Endothelin-1 (ET-1)-potentiated insulin secretion: involvement of protein kinase C and the ET(A) receptor subtype. Metab Clin Exp. 2000;49(2):264\u20139.","journal-title":"Metab Clin Exp."},{"issue":"3","key":"1117_CR43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2337\/db06-1406","volume":"56","author":"A Lteif","year":"2007","unstructured":"Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese\/insulin-resistant humans. Diabetes. 2007;56(3):728\u201334.","journal-title":"Diabetes"},{"issue":"4","key":"1117_CR44","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/en.2006-0654","volume":"148","author":"CC Juan","year":"2007","unstructured":"Juan CC, Chuang TY, Chang CL, Huang SW, Ho LT. Endothelin-1 regulates adiponectin gene expression and secretion in 3T3-L1 adipocytes via distinct signaling pathways. Endocrinology. 2007;148(4):1835\u201342.","journal-title":"Endocrinology"},{"issue":"8","key":"1117_CR45","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.2337\/db10-1281","volume":"60","author":"A Shemyakin","year":"2011","unstructured":"Shemyakin A, Salehzadeh F, Esteves Duque-Guimaraes D, B\u00f6hm F, Rullman E, Gustafsson T, et al. Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes. 2011;60(8):2061\u20137.","journal-title":"Diabetes"},{"issue":"5","key":"1117_CR46","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2337\/dc05-2179","volume":"29","author":"MA Abdul-Ghani","year":"2006","unstructured":"Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130\u20139.","journal-title":"Diabetes Care"},{"issue":"6","key":"1117_CR47","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1210\/endo.137.6.8641217","volume":"137","author":"A Mart\u00ednez","year":"1996","unstructured":"Mart\u00ednez A, Weaver C, L\u00f3pez J, Bhathena SJ, Elsasser TH, Miller MJ, et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology. 1996;137(6):2626\u201332.","journal-title":"Endocrinology"},{"issue":"2","key":"1117_CR48","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1006\/bbrc.1998.8261","volume":"244","author":"Y Isumi","year":"1998","unstructured":"Isumi Y, Minamino N, Kubo A, Nishimoto N, Yoshizaki K, Yoshioka M, et al. Adrenomedullin stimulates interleukin-6 production in Swiss 3T3 cells. Biochem Biophys Res Commun. 1998;244(2):325\u201331.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1117_CR49","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/HJH.0000000000001893","volume":"37","author":"T Ohlsson","year":"2019","unstructured":"Ohlsson T, Nilsson PM, Persson M, Melander O. Midregional proadrenomedullin predicts reduced blood pressure and glucose elevation over time despite enhanced progression of obesity markers. J Hypertens. 2019;37(3):590\u20135.","journal-title":"J Hypertens"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01117-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T05:34:41Z","timestamp":1634362481000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01117-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01117-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The KORA F4\/FF4 study was approved by the local authorities and carried out in accordance with the Declaration of Helsinki. The ethics approval number is EC No. 06068. All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}